MAP2K7 and hepatocellular carcinoma: To inhibit tumor cell proliferation, it also inhibits various RAF kinases directly and inhibits the downstream RAF/MEK/ERK signal transduction pathways.[8] In the ZGDH3 study on advanced hepatocellular carcinoma,[4] overall survival of the donafenib group was better than that of the sorafenib group.